High oxygen saturation (94% to 99%) at or after 32 weeks postmenstrual age is associated with which risk for progression to severe retinopathy of prematurity (ROP)?

Enhance your readiness for the MEDNAX Neonatal Nurse Practitioner Exam. Utilize flashcards, multiple-choice questions, and detailed explanations. Equip yourself for success!

Multiple Choice

High oxygen saturation (94% to 99%) at or after 32 weeks postmenstrual age is associated with which risk for progression to severe retinopathy of prematurity (ROP)?

Explanation:
Maintaining higher oxygen saturation once a preterm infant reaches 32 weeks postmenstrual age or later is linked to a lower risk of progressing to severe retinopathy of prematurity. The retina, at this stage, benefits from enough oxygen to keep the tissue from becoming chronically hypoxic, which would otherwise drive VEGF-mediated neovascularization and progression to more serious disease. So, in this later window, stable, adequately high oxygen levels help prevent the hypoxia-driven changes that lead to severe ROP. It’s worth noting that oxygen management is complex: early in life, excessive oxygen can contribute to initial ROP development, but after about 32 weeks PMA, higher saturations are associated with decreased progression risk.

Maintaining higher oxygen saturation once a preterm infant reaches 32 weeks postmenstrual age or later is linked to a lower risk of progressing to severe retinopathy of prematurity. The retina, at this stage, benefits from enough oxygen to keep the tissue from becoming chronically hypoxic, which would otherwise drive VEGF-mediated neovascularization and progression to more serious disease. So, in this later window, stable, adequately high oxygen levels help prevent the hypoxia-driven changes that lead to severe ROP. It’s worth noting that oxygen management is complex: early in life, excessive oxygen can contribute to initial ROP development, but after about 32 weeks PMA, higher saturations are associated with decreased progression risk.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy